Experimental cancer treatments for advanced stages are more effective than previously thought. Some oncology practitioners believe that experimental drugs are harmful - they give false hope to patients because of its low efficiency (long anticipated effectiveness of the experimental treatment with special drugs produced in Canadian pharmacy only at the level of 4-6% of cases). Patients in the final stage of the disease should have greater access to information about the experimental treatment programs, and, accordingly, they and their families should have the right to know what their real chances, with a particular treatment strategy. Scientists believe that the involvement of cancer patients even in the early stages of clinical trials can be very useful for them. Besides, the search for a way out of the situation means continuing the fight against the disease. It is characterized by academic phrase "treatment of metastatic cancer still remains palliative, with a very low probability of complete remission and cure the disease."

Region Hovedstaden

Objectives: The participants from the Center for Cancer Immune Therapy (CCIT) actively participate in the clinical trial and are involved in the biobanking. To the scientific part, CCIT will conduct comprehensive research on T cell epitope identification and T cell biology as well as immune escape mechanisms of MCC.

Expertise relevant to the proposed work: CCIT is a research center focused on development and testing of immunological treatment of cancer. CCIT has a research profile based on equally weighted experimental and clinical projects. The laboratory has extensive experience in characterization of tumor antigens recognized by CD8+ T cells, studies of T cell and DC biology, and biological monitoring of vaccination trials. To the clinical part, more than 150 cancer patients have been vaccinated with dendritic cell based therapeutic vaccinations, and currently 6 clinical trials are active, 5 of which include cell transfer to cancer patients.

Specific role in the project: CCIT will participate in WPs 1, 2, 3 and 5. CCIT will actively participate in the clinical trial and will conduct research on T cell epitope identification and T cell biology, such as activation and functionality studies. The center will lead WP 3. CCIT will be heavily involved in the clinical testing and the subsequent monitoring of immune responses.


Region Hovedstaden
Kongens Vaenge 2
3400 Hillerod